The United Kingdom and the United States have secured a key commercial pact that will maintain no tariffs on British drug exports being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to boost spending on drugs through the NHS. This move ensures that tariffs on these crucial exports will stay at nothing for a timeframe of 36 months.
This agreement comes after earlier statements to significantly raise tariffs on patented drug imports, with increases mentioned up to 100%.
"This agreement with the UK bolsters the global environment for innovative medicines and introduces much-needed balance to American-British drug exports," a release said.
Trade Importance
Medicines constitute one of the the United Kingdom's largest goods shipped to the US, which is clearly the primary market for large companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period prior to September, the UK shipped drugs worth over eleven billion pounds to the US. This value represented nearly one-fifth of British export trade in that period.
"This guarantee protects employment, boosts funding and sets the stage for the UK to become a international leader for biotech and pharma," a minister stated.
Key British Pledges
The agreement includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to double total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to stay within budget will be limited at 15%. Previously, refunds were more than twenty percent.
Industry Background
The deal comes amid a protracted dispute between the drug companies and the ministers over medicine costs and regulatory access.
The disagreement were exacerbated by claims that US consumers were paying several times more for the same drugs than consumers in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been pledged toward American operations.
One official stated that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the last ten years.